Immunosuppressive Drugs in Cutaneous Lupus Erythematosus

  • Michael Sticherling


Systemic Lupus Erythematosus Mycophenolate Mofetil Cefuroxime Axetil Cutaneous Lupus Erythematosus Discoid Lupus Erythematosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abe Y, Seno A, Tada J, Arata J (1994) Discoid lupus erythematosus: successful treatment with oral methotrexate. Arch Dermatol 130:938–939CrossRefPubMedGoogle Scholar
  2. Abud-Mendoza C, Sturbaum AK, Vazquez-Compean R, Gonzalez-Amaro R (1993) Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 20:731–733PubMedGoogle Scholar
  3. Abu-Shakra M, Buskila D (2002) Update on the treatment of systemic lupus erythematosus: therapeutic highlights from the Sixth International Lupus Conference. Isr Med Assoc J 4:71–73PubMedGoogle Scholar
  4. Abu-Shakra M. Shoenfeld Y(2001) Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 10:152–153CrossRefPubMedGoogle Scholar
  5. Arbisier JL, Moschella SL (1995) Clofazimine. Areview of its medical uses and mechanisms of action. J Am Acad Dermatol 32:241–247CrossRefPubMedGoogle Scholar
  6. Asherson RA, Lahita RG (1991) Sex hormone modulation in systemic lupus erythematosus. Stil l a therapeutic option? Ann Rheum Dis 50:897–898PubMedGoogle Scholar
  7. Ashinoff R, Werth VP, Frank AG Jr (1988) Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol 19:961–965PubMedGoogle Scholar
  8. Ayers S Jr, Mihan R (1974) Lupus erythematosus and vitamin E:an effective and non-toxic therapy. Cutis 23:49–52Google Scholar
  9. Bergman J, Rico MJ (2001) Tacrolimus clinical studies for atopic dermatitis and other conditions. Semin Cutan Med Surg 20:250–259PubMedGoogle Scholar
  10. Boehm I, Bieber T (2001) Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 137:235–236PubMedGoogle Scholar
  11. Boehm IB, Boehm GA, Bauer R (1998) Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 18:59–62CrossRefPubMedGoogle Scholar
  12. Bohm L, Uerlich M, Bauer R (1997) Rapid improvement of subacute lupus erythematosus with low-dose methotrexate. Dermatology 194:307–308PubMedGoogle Scholar
  13. Bottomley WW, Goodfield MJ (1995a) Methotrexate for the treatment of discoid lupus erythematosus. Br J Dermatol 133:655–656PubMedGoogle Scholar
  14. Bottomley WW, Goodfield MJ (1995b) Methotrexate for the treatment of severe mucocutaneous lupus erythematosus. Br J Dermatol 133:311–314PubMedGoogle Scholar
  15. Burkhardt H, Kalden JR (1997) Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Rheumatol Int 17:85–90CrossRefPubMedGoogle Scholar
  16. Callen JP (2002) Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 16:245–264CrossRefPubMedGoogle Scholar
  17. Callen JP, Spencer LV, Burruss JB, Holtman J (1991) Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 127:515–522CrossRefPubMedGoogle Scholar
  18. Carmichael AJ, Paul CJ (1991) Discoid lupus erythematosus responsive to sulphasalazine. Br J Dermatol 125:291–294Google Scholar
  19. Cohen Y, Nagler A(2002) Treatment of refractory autoimmune diseases with lymphoablation and hematopoietic stem cell support. Isr Med Assoc J 4:865–867PubMedGoogle Scholar
  20. Conti F, Priori R, Alessandri C, Spinelli FR, Medda E, Valesini G(2000) Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A. Lupus 9:676–680CrossRefPubMedGoogle Scholar
  21. Cronstein BN (1996) Molecular therapeutics. Methotrexateand its mechanism of action. Arthritis Rheum 39:1951–1960PubMedGoogle Scholar
  22. Dalziel K, Going G, Cartwright PH, Marks R, Beveridge GW, Rowell NR (1986) Treatment of chronic discoid lupus erythematosus with an oral gold component (aurano fin). Br J Dermatol 115:211–216PubMedGoogle Scholar
  23. De Vita S, Ferraccioli GF, Di Poi E, Bartoli E, Bombardieri S (1996) High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience. Clin Exp Rheumatol 14:S85–92PubMedGoogle Scholar
  24. De Bandt M, Descamps V, Meyer O (2001) Etanercept-induced systemic lupus erythematosus: two cases on patients with rheumatoid arthritis. Lupus 10:S118Google Scholar
  25. Delaporte E, Catteau B, Sabbagh N, Gosselin P, Breuillard F, Doutre M-S, Broly F, Piette F, Bergoend H (1997) Traitementdu lupus erythemateux chronique parla sulfasalazine: 11 observations. Ann Dermatol Venereol 124:151–156PubMedGoogle Scholar
  26. Dequet CR, Wallace DJ (2001) Novel therapies in the treatment of systemic lupus erythematosus. Curr Opin Investig Drugs 2:1045–1053PubMedGoogle Scholar
  27. Duddridge M, Powell RJ (1997) Treatment of severeand difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56:690–692PubMedGoogle Scholar
  28. Duna GF, Cash JM (1995) Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 21:99–115PubMedGoogle Scholar
  29. Dutz JP, Ho VC (1998) Immunosuppressive agents in dermatology. An update. Dermatol Clin 16:235–251CrossRefPubMedGoogle Scholar
  30. Englert HJ, Hughes GVR (1988) Danazol and discoid lupus. Br J Dermatol 119:407–409PubMedGoogle Scholar
  31. Ferda A (1996) Efficacy of sulfasalazinein discoid lupus erythematosus. Int J Dermatol10:746–748Google Scholar
  32. Furst DE (1999) Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors. Rheumatology(Oxford) 38:14–18CrossRefGoogle Scholar
  33. Furst DE (2002) Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol 14:220–224CrossRefPubMedGoogle Scholar
  34. Furukawa F, Imamura S, Takigawa M (1995) FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lprmice. Arch Dermatol Res 287:558–563CrossRefPubMedGoogle Scholar
  35. Garcia-Porrua C, Gonzales Gay MA, Fernandez-Lamelo F, Paz-Carreira JM, Lavilla E, Gonzales-Lopez MA (1998) Simultaneous development of SLE-like syndrome and autoimmune thyroiditis following alpha-interferon treatment. Clin Exp Rheumatol 16:107–108PubMedGoogle Scholar
  36. Gasparro FP(2000) Photodermatology: progress, problems and prospects. Eur J Dermatol 10:250–254Google Scholar
  37. Gelfand EW (2001) Antibody-directed therapy: Past, present and future. J Allergy Clin Immunol 108:111–116CrossRefGoogle Scholar
  38. Genereau T, Chosidow O, Danel C, Cherin P, Herson S (1999) High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 135:1124–1125CrossRefPubMedGoogle Scholar
  39. Gescuk BD, Davis JC Jr (2002) Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 14:515–521CrossRefPubMedGoogle Scholar
  40. Glant TT, Mikecz K, Brennan F, Negroiu G, Bartlett R (1998) Suppression of autoimmune responses and inflammatory events by leflunomide in an animal model for rheumatoid arthritis. J Rheumatol 25:20–26Google Scholar
  41. Goldberg JW, Lidsky MD (1984) Pulse methylprednisolone therapyforpersist ent subacutecutaneous lupus. Art hritis Rheum 27:837–838Google Scholar
  42. Goldstein E, Carey W (1994) Discoid lupus erythematosus: successful treatment with oral methotrexate. Arch Dermatol 130:938–939CrossRefPubMedGoogle Scholar
  43. Goyal S, Noussari HC (2001) Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 45:142–144CrossRefPubMedGoogle Scholar
  44. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS (1991) Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Reumatol 18:1621–1622Google Scholar
  45. Gratwohl A, Passweg J, Gerber I, Tyndall A (2001) International Stem Cell Project for Autoimmune Diseases. Stem cell transplantation for autoimmune diseases. Best Pract Res Clin Haematol 14:755–776CrossRefPubMedGoogle Scholar
  46. Griffiths B, Emery P (2001) The treatment of lupus with cyclosporine A. Lupus 10:165–170CrossRefPubMedGoogle Scholar
  47. Hanjani NM, Noussari CH (2002) Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 138:1616–1618CrossRefPubMedGoogle Scholar
  48. Hazelton RA, McCruden AB, Sturrock RD, Stimson WH (1983) Hormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19-nortestosterone. Ann Rheum Dis 42:155–157PubMedGoogle Scholar
  49. Isaacs JD (2001) From bench to bedside: discovering rules for antibody design, and improving serotherapy with monclonal antibodies. Rheumatol 40:724–738CrossRefGoogle Scholar
  50. Isenberg D, Leckie MJ (2002) Biological treatments for systemic lupus erythematosus. Scand J Rheumatol 31:187–191CrossRefPubMedGoogle Scholar
  51. Jansen GT, Dillaha CJ, Honeycutt WM (2001) Discoid lupus erythematosus. Is systemic treatment necessary? Arch Dermatol 92:283–285CrossRefGoogle Scholar
  52. Jayne D (1999) Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens 8:563–567CrossRefPubMedGoogle Scholar
  53. Jeffes EW 3rd, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G(1995) Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth — inhibitory effects of methotrexate. J Invest Dermatol 104: 183–188CrossRefPubMedGoogle Scholar
  54. Jessop S, Whitelaw D, Jordaan F (2001) Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev CD002954Google Scholar
  55. Jolles S, Hughes J, Whittaker S (1998) Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 134:80–86CrossRefPubMedGoogle Scholar
  56. Jungers P, Kuttenn F, Liote F, Pelissier C, Athea N, Laurent MC, Viriot J, Dougados M, Bach JF (1985) Hormonal modulation in systemic lupus erythematosus. Preliminary clinical and hormonal results with cyproterone acetate. Arthritis Rheum 28:1243–1250PubMedGoogle Scholar
  57. Karim MY, Alba P, Cuadrado MJ, Abbs IC, D’Cruz DP, Khamashta MA, Hughes GR (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 41:876–882CrossRefPubMedGoogle Scholar
  58. Kilian K, Banyai A, Karadi A, Miklos K, Patranyi GG, Paloczi K (1998) FK-506 (tacrolimus) therapy for an unusual SLE-like disease. Transplant Proc 30:4130–4131CrossRefPubMedGoogle Scholar
  59. Knobler RM, Graninger W, Lindmaier A, Trautinger F, Smolen JS (1992) Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. Arthrit Rheum 32:319–324Google Scholar
  60. Krivanek JFC, Paver WKA (1980) Further studies on the use of clofazimine in discoid lupus erythematosus. Australas J Dermatol 21:169–171PubMedGoogle Scholar
  61. Kuhn A, Specker C, Ruzicka T, Lehmann P (2002) Methotrexatetr eatment for refractory subacutecut aneous lupus erythematosus. J Am Acad Dermatol 46:600–603CrossRefPubMedGoogle Scholar
  62. Kurtz ES, Bayley SC, Arshad F, Lee AA, Przekop PA (1995) Leflunomide: an active antiin-flammatory and antiproliferative agent in models of dermatologic disease. Inflamm Res 44:187–188CrossRefPubMedGoogle Scholar
  63. Lernia VD, Bisighini G (1996) Discoid lupus erythematosus during treatment with cyclosporine. Acta Derm Venereol 76:87–88PubMedGoogle Scholar
  64. Luger T (2001) Treatment of immune-mediated skin diseases: future perspectives. Eur J Dermatol 11:343–347PubMedGoogle Scholar
  65. Machlod KP, Smolen JS (1990) Interferon-gamma induced exacerbation of systemic lupus erythematosus. J Rheumatol 17:831–832PubMedGoogle Scholar
  66. Martinez J, de Misa RF, Torrelo A, Ledo A (1992) Low-dose intralesional interferon alfa for discoid lupus erythematosus. J Am Acad Dermatol 26:494–496PubMedGoogle Scholar
  67. Martinez J, de Misa RF, Boixeda P, Arrazola JM, Ledo A (1993) Long-term results of intralesional interferon alpha-2B in discoid lupus erythematosus. J Dermatol 20:444–446PubMedGoogle Scholar
  68. Masse R, Youinou P, Dorval JC, Cledes J(1980) Reversal of lupus-erythematosus-like disease with danazol. Lancet 20:651CrossRefGoogle Scholar
  69. McCauliffe DP (2001) Cutaneous lupus erythematosus. Semin Cutan Med Surg 20:14–26PubMedGoogle Scholar
  70. McGrath HJ (1994) Ultraviolet A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 12:129–135PubMedGoogle Scholar
  71. McGrath H Jr(1997) Prospects for UV-A1 therapy as a treatment modality in cutaneous and systemic LE: Lupus 6:209–217Google Scholar
  72. McGrath HJ (1999) Ultraviolet A1 (340–400 nm) irradiation and systemic lupus erythematosus. J Invest Dermatol 4:79–84Google Scholar
  73. McGrath HJ, Bak E, Michalski JP (1987) Ultraviolet-A light prolongs survival and improves immune function (New Zealand black × New Zealand white) F1 hybrid mice. Arthritis Rheum 30:557–561PubMedGoogle Scholar
  74. McGrath HJ, Martinez-Osuna P, Lee FA (1996) Ultraviolet A1 (340–400 nm) irradiation therapy in systemic lupus erythematosus. Lupus 5:269–274PubMedGoogle Scholar
  75. Millard TP, Hawk JLM (2001) Ultraviolet therapy in lupus. Lupus 10:185–187PubMedGoogle Scholar
  76. Molina N, McGrath H Jr. Longterm ultraviolet A1 irradiation therapy in systemic lupus erythematosus. J Rheumatol 24:1072–1074Google Scholar
  77. Moore J, Tyndall A, Brooks P (2001) Stem cells in the aetiopathogenesis and therapy of rheumatic disease. Best Pract Res Clin Rheumatol 15:711–726PubMedGoogle Scholar
  78. Morley KD, Parke A, Hughes GRV (1982) Systemic lupus erythematosus: two patients treated with danazol. Br Med J 284:1431–1432Google Scholar
  79. Morris LF, Lemak NA, Arnett FC Jr, Jordon RE, Duvic M (1996) Systemic lupus erythematosus diagnosed during interferon alfa therapy. South Med J 89:810–814PubMedGoogle Scholar
  80. Nicolas JF, Thivolet J (1989) Interferon alpha therapy in severe unresponsive subacute cutaneous lupus erythematosus. N Engl J Med 321:1550–1551PubMedGoogle Scholar
  81. Nicolas JF, Thivolet J, Kanitakis J, Lyonnet S (1990) Response of discoid and subacute cutaneous lupus erythematosus to recombinant interferon alpha 2a. J Invest Dermatol 95:142S–145SCrossRefPubMedGoogle Scholar
  82. Nousari HC, Kimyai-Asadi A, Tausk FA (1998) Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 352:1925–1825CrossRefGoogle Scholar
  83. Obermoser G, Weber F, Sepp N (2001) Discoid lupus erythematosus in a patient receiving cyclosporin for liver transplantation. Acta Derm Venereol 81:319CrossRefPubMedGoogle Scholar
  84. Openshaw H, Nash RA, McSweeney PA (2002) High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. Biol Blood Marrow Transplant 8:233–248CrossRefPubMedGoogle Scholar
  85. Parnham MJ (1995) Leflunomide: a potential new disease modifying anti-rheumatic drug. Exp Opin Invest Drugs 4:777–779Google Scholar
  86. Patel PP, Werth V(2002) Cutaneous lupus erythematosus: a review. Dermatol Clin 20:373–385CrossRefPubMedGoogle Scholar
  87. Piette JC (1995) High-dose immunoglobulins in the treatment of refractory cutaneous lupus erythematosus. Open trial in 5 cases. Art hritis Rheum 38:S304Google Scholar
  88. Piette JC, Du LT, Papo T (1995) Postmenopausal hormone therapy and systemic lupus erythematosus. Ann Intern Med 122:961–962Google Scholar
  89. Pisetksky DS (2000) Tumor necrosis α blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 43:2381–2382CrossRefPubMedGoogle Scholar
  90. Prinz JC, Meurer M, Reiter C, Rieber EP, Plewig G, Riethmuller G (1996) Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J Am Acad Dermatol 34:244–252PubMedGoogle Scholar
  91. Reid C(2000) Drug treatmentof cutaneous lupus. Am J Clin Dermatol 1:375–379Google Scholar
  92. Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10:480–483CrossRefPubMedGoogle Scholar
  93. Richter HI, Krutmann J, Goerz G (1998) Extrakorporale Photopherese bei therapie-refraktärem disseminiertem diskoiden Lupus erythematodes. Hautarzt 49:487–491CrossRefPubMedGoogle Scholar
  94. Robert C, Kupper TS (1999) Inflammatory skin diseases, T cells and immune surveillance. N Engl J Med 341:1817–1828CrossRefPubMedGoogle Scholar
  95. Rodriquez-Castellanos MA, Rubio JB, Gomez JFB, Mendoza AG (1995) Phenytoin in the treatment of discoid lupus erythematosus. Arch Dermatol 131:620–621CrossRefGoogle Scholar
  96. Ronnblom LE, Alm GV, Oberg KE (1991a) Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115:178–183PubMedGoogle Scholar
  97. Ronnblom LE, Alm GV, Oberg KE (1991b) Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 30:537–540PubMedGoogle Scholar
  98. Rothenberg RJ, Graziano FM, Grandone JT, Goldberg JW, Bjarnason DF, Finesilver AG (1988) The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 31:612–615PubMedGoogle Scholar
  99. Rudnicka L, Szymanska E, Walecka I, Slowinska M (2000) Long-term cefuroxime axetil in subacute cutaneous lupus erythematosus. Dermatology 200:129–131CrossRefPubMedGoogle Scholar
  100. Russell-Jones R(2000) Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 142:16–21Google Scholar
  101. Rutter A, Luger T(2001) High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 44:1010–1024CrossRefPubMedGoogle Scholar
  102. Sacher RA (2001) Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 108:139–146CrossRefGoogle Scholar
  103. Saeki Y, Oshima S, Kurimoto I, Miura H, Suemura M (2000) Maintaining remission of lupus erythematosus profundus (LEP) with cyclosprin A. Lupus 9:390–392CrossRefPubMedGoogle Scholar
  104. Schanz S, Ulmer A, Rassner G, Fierlbeck G (2002) Successful treatment of subacute lupus erythematosus with mycophenolate mofetil. Br J Dermatol 147:174–178CrossRefPubMedGoogle Scholar
  105. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M (1991) Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68:1536–1537PubMedGoogle Scholar
  106. Schulz EJ, Menter MA (1971) Treatment of discoid and subacutecut aneous lupus erythematosus with cyclophosphamide. Br J Dermatol 85:60–65Google Scholar
  107. Singer NG, McCune WJ (1998) Update on immunosuppressive therapy. Curr Opin Rheumatol 10:169–173PubMedGoogle Scholar
  108. Solsky M, Wallace DJ (2002) New therapies in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 16:293–312CrossRefPubMedGoogle Scholar
  109. Sonnichsen N, Meffert H, Kunzelmann V, Audring H (1993) UV-A-1 therapy of subacute cutaneous lupus erythematosus. Hautarzt 44:723–725PubMedGoogle Scholar
  110. Steinkjer B(1995) Auranofin in the treatment of discoid lupus erythematosus. J Dermatol Treat 2:27–29Google Scholar
  111. Sticherling M(2001) Chronic cutaneous lupus erythematosus. In: Hertl M (ed) Autoimmune disease of the skin — pathogenesis, diagnosis, management. Springer, Vienna Berlin Heidelberg New York,pp 337–364Google Scholar
  112. Sturgess AD, Evans DT, Mackay IR, Riglar A (1984) Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 13:11–14PubMedGoogle Scholar
  113. Tan BB, Lear TJ, Gawkrodger DJ, English JS (1997) Azathioprine in dermatology: a survey of current practice in the UK. Br J Dermatol 136:351–355CrossRefPubMedGoogle Scholar
  114. Thivolet J, Nicolas JF, Kanitakis J, Lyonnet S, Chouvet B(1990) Recombinantin terferon alpha 2a is effective in the treatment of discoid and subacutecut aneous lupus erythematosus. Br J Dermatol 122:405–409PubMedGoogle Scholar
  115. Thoma-Uszynski S, Hertl M (2001) Novel therapeutic approaches in autoimmune skin disorders. In: Hertl M (ed) Autoimmune disease of the skin — pathogenesis, diagnosis, management. Springer, Vienna Berlin Heidelberg New York, pp 337–364Google Scholar
  116. Torrelo A, Espana A, Medina S, Ledo A (1990) Danazol and discoid lupus erythematosus. Dermatologica 181:239PubMedGoogle Scholar
  117. Tran QHD, Guay E, Chartier S, Tousignant J (2001) Tacrolimus in dermatology. J Cutan Med Surg 5:329–335PubMedGoogle Scholar
  118. Traynor AE, Barr WG, Rosa RM, Rodriguez J, Oyama Y, Baker S, Brush M, Burt RK (2002) Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 46:2917–2923CrossRefPubMedGoogle Scholar
  119. Tsokos GC, Caughman SW, Klippel JH (1985) Successful treatment of generalized discoid lesions with azathioprine. Its use in apatient s with systemic lupus erythematosus. Arch Dermatol 121:1323–1325CrossRefPubMedGoogle Scholar
  120. Tyndall A, Koike T (2002) High-dose immunoablative therapy with hematopoietic stem cell support in the treatment of severe autoimmune disease: current status and future direction. Intern Med 41:608–612PubMedGoogle Scholar
  121. Tyndall A, Passweg J, Grathwohl A (2000) Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases. Ann Rheum Dis 60:702–707CrossRefGoogle Scholar
  122. Walker SL, Kirby B, Chalmers RJ (2002) The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 147:405–406CrossRefPubMedGoogle Scholar
  123. Wallace D (2001) Currentand emerging lupus treatments. Am J Manag Care 7:S490–495PubMedGoogle Scholar
  124. Wallace DJ (2002) Management of lupus erythematosus: recent insights. Curr Opin Rheumatol 14:212–219CrossRefPubMedGoogle Scholar
  125. Warner LM, Cummons T, Nolan L, Sehgal SN (1995) Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse. Inflamm Res 44:S205–206CrossRefPubMedGoogle Scholar
  126. Watts RA (2000) Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol 12:49–54CrossRefPubMedGoogle Scholar
  127. Werth V (2001) Current treatment of cutaneous lupus erythematosus. Dermatol Online J 7:2–12Google Scholar
  128. Werth VP (1993) Management and treatment with systemic glucocorticoids. Adv Dermatol 8:81–101PubMedGoogle Scholar
  129. Wilder RL (1998) Hormones, pregnancy, and autoimmune diseases. Ann NY Acad Sci. 840:45–50PubMedGoogle Scholar
  130. Wilke WS, Krall PL, Scheetz RJ, Babiak T, Danao T, Mazanec DJ, Segal AM, Clough JD (1991) Methotrexate for systemic lupus erythematosus:a retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 9:581–587PubMedGoogle Scholar
  131. Wollina U, Looks A (1999) Extracorporeal photochemotherapy in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 13:127–130CrossRefPubMedGoogle Scholar
  132. Yell JA, Burge SM (1994) Cyclosporine and discoid lupus erythematosus. Br J Dermatol 131:132–133PubMedGoogle Scholar
  133. Yocum DE (1996) Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 22:133–154CrossRefPubMedGoogle Scholar
  134. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F(2002) Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 12:50–52PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 2005

Authors and Affiliations

  • Michael Sticherling

There are no affiliations available

Personalised recommendations